Patents Examined by Peter P. Tung
  • Patent number: 6001594
    Abstract: The invention provides a human testin (HTES) and polynucleotides which identify and encode HTES. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HTES.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: December 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Karl J. Guegler, Neil C. Corley
  • Patent number: 5998195
    Abstract: A plasmid for expression of Moloney Murine Leukemia Virus-derived reverse transcriptase in E. coli cells deficient in the expression of indiginous RNAse activity, a method for purification of the recombinant enzyme, and a composition comprising a cloned and purified reverse transcriptase opimized for use in cDNA and nucleic acid amplification procedures.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: December 7, 1999
    Assignee: Gen-Probe Incorporated
    Inventors: Daniel Louis Kacian, Michael Garth Riggs, James Garfield Putnam
  • Patent number: 5989869
    Abstract: The present invention is directed to a process for improving daunorubicin and doxorubicin production by means of a recombinant microorganism in which a gene of daunorubicin metabolism involved in the glycosylation of daunorubicin to acid-sensitive, baumycin-like compounds is inactivated.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: November 23, 1999
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Silvia Filippini, Natalia Lomovskaya, Leonid Fonstein, Anna Luisa Colombo, C. Richard Hutchinson
  • Patent number: 5985638
    Abstract: The present invention provides a human microsomal signal peptidase subunit (HMSP) and polynucleotides which encode HMSP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HMSP.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: November 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 5981242
    Abstract: The invention provides a human amino acid permease homolog (AAPH) and polynucleotides which identify and encode AAPH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of AAPH.
    Type: Grant
    Filed: February 3, 1999
    Date of Patent: November 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Henry Yue, Neil C. Corley
  • Patent number: 5972684
    Abstract: The invention provides a human carbonic anhydrase isoform (CAVIII) and polynucleotides which identify and encode CAVIII. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of CAVIII.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: October 26, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Henry Yue, Sara R. Greenwald, Neil C. Corley
  • Patent number: 5968798
    Abstract: The invention provides a human glutaredoxin .beta. (GRX.beta.) and polynucleotides which identify and encode GRX.beta.. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GRX.beta..
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: October 19, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
  • Patent number: 5962302
    Abstract: The invention provides a human N-acetylneuraminate lyase (HNANL) and polynucleotides which identify and encode HNANL. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HNANL.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: October 5, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley
  • Patent number: 5962297
    Abstract: Disclosed are a polypeptide having a .beta.-fructofuranosidase activity obtainable by the expression of a microbial gene, a DNA encoding the polypeptide, a transformant obtained by introducing the DNA into an appropriate host, a process for producing the polypeptide comprising culturing the transformant to produce the polypeptide and collecting the produced polypeptide from the culture, and a method for fructofuranosyl transfer comprising a step of reacting a fructofuranosyl donor with a fructofuranosyl acceptor in the presence of the polypeptide.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: October 5, 1999
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Keiji Tsusaki, Michio Kubota, Hiroto Chaen
  • Patent number: 5959081
    Abstract: A substantially pure S2-6 protein (a) having a zinc binding LIM domain, (b) whose mRNA is preferentially expressed in nonproliferating or growth inhibited human diploid fibroblasts, (c) whose mRNA is overexpressed in senescent human diploid fibroblasts or human diploid fibroblasts derived from a patient with Werner Syndrome, and (c) whose mRNA expression is reduced or abolished in fetal human diploid fibroblasts, immortalized cells, cancerous cells and other highly proliferative cells.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: September 28, 1999
    Assignee: The Board of Trustees of the University of Arkansas
    Inventor: Beata Lecka-Czernik
  • Patent number: 5942399
    Abstract: The invention provides a human amino acid permease homolog (AAPH) and polynucleotides which identify and encode AAPH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of AAPH.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: August 24, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Henry Yue, Neil C. Corley
  • Patent number: 5928925
    Abstract: An object of the present invention is to isolate complementary DNA coding for ornithine carbamyltransferase derived from a rice plant, necessary for development of a plant ornithine carbamyltransferase gene mutated to have phaseolotoxin resistance, and further to establish an expression system in microorganisms for simply evaluating the functions of the gene mutated to have resistance. This object is solved by a rice ornithine carbamyltransferase gene coding for a protein consisting of the amino acid sequence shown in SEQ ID NO:6 in the Sequence Listing, a plasmid vector containing the gene, and a transformant carrying the plasmid vector.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: July 27, 1999
    Assignee: Director of National Food Research Institute, Ministry of Agriculture, Forestry and Fisheries
    Inventors: Yoshifumi Ito, Akihiro Hino, Hirohito Miura
  • Patent number: 5919686
    Abstract: The invention provides two human NADH dehydrogenase subunits (HNDS) and polynucleotides which identify and encode HNDS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HNDS.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: July 6, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman, Karl J. Guegler, Purvi Shah
  • Patent number: 5914390
    Abstract: Methods are disclosed for increasing the yields of recombinant proteins. Addition of one or more protective agents, such as a sulfated compound (including heparin, heparin sulfate, sodium dodecyl sulfate, and the like), hyaluronic acid or deoxycholate, to recombinant protein production processes is disclosed. Addition of protective agents to the recombinant production process results in increased yields of recombinant proteins.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: June 22, 1999
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Ranga Nathan, Henryk Cudny
  • Patent number: 5876997
    Abstract: The invention provides a purified phytate enzyme derived from Escherichia coli B. The enzyme has a molecular weight of about 47.1 kilodaltons and has phytase activity (SEQ ID NO:2). The enzyme can be produced from native or recombinant host cells and can be used to aid in the digestion of phytate where desired. In particular, the phytase of the present invention can be used in animal feed.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: March 2, 1999
    Assignee: Diversa Corporation
    Inventor: Keith Kretz
  • Patent number: 5869289
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human galectin-8. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding human galectin-8. The invention also provides for the production and use of substantially purified human galectin-8 in pharmaceutical compositions to increase immune responses. The invention also provides for the use of antisense molecules and antibodies in pharmaceutical compositions to decrease immune response. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts and/or genomic DNA encoding human galectin-8 and anti-human galectin-8 antibodies which specifically bind to human galectin-8.
    Type: Grant
    Filed: October 9, 1996
    Date of Patent: February 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Olga Bandman
  • Patent number: 5869309
    Abstract: The instant invention provides nucleic acid molecules encoding cephalosporin esterase from Rhodosporidium toruloides. In addition, the invention provides isolated cephalosporin esterase, expression vectors, host cells, and methods of producing cephalosporin esterase.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: February 9, 1999
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Michael Politino, Sean M. Tonzi, John J. Usher, William V. Burnett, Guna Romancik
  • Patent number: 5869307
    Abstract: The invention provides a novel GDP-mannose 4,6-dehydratase.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: February 9, 1999
    Assignee: Genetics Institute, Inc.
    Inventors: Francis Sullivan, Ronald Kriz, Ravindra Kumar
  • Patent number: 5866391
    Abstract: The present invention relates to Aspergillus porphobilinogen synthases and isolated nucleic acid fragments comprising nucleic acid sequences encoding the porphobilinogen synthases as well as nucleic acid constructs, vectors, and recombinant host cells comprising the nucleic acid sequences. The invention also relates to methods of producing the porphobilinogen synthases.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: February 2, 1999
    Assignee: Novo Nordisk Biotech, Inc.
    Inventors: Aubrey Jones, Joel R. Cherry
  • Patent number: 5861294
    Abstract: The present invention provides an adenosine kinase protein having an identified structural formula. The identified protein or similar adenosine kinase proteins having residues as claimed and recited herein may be isolated and purified from natural sources or produced by recombinant DNA technology.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 19, 1999
    Assignee: Abbott Laboratories
    Inventors: Marlon Daniel Cowart, Donald N. Halbert, James F. Kerwin, Jr., Teresa McNally